Ratings by Rodman & Renshaw (Michael King Jr.)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/15/2026 | Elicio Therapeutics | ELTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | Kyntra Bio | KYNB | New Coverage | Buy (N/A) |
6.63 (7.00) |
5.58% | Details | |
| 5/28/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
5.28 (4.22) |
-20.08% | Details | |
| 5/11/2026 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
3.51 (3.30) |
-5.98% | Details | |
| 4/15/2026 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
3.15 (2.50) |
-20.63% | Details | |
| 3/17/2026 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
1.54 (1.32) |
-14.29% | Details | |
| 3/9/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Buy (N/A) |
8.77 (9.47) |
7.98% | Details | |
| 3/9/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.63 (3.73) |
-67.93% | Details | |
| 1/13/2026 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
1.35 (1.26) |
-6.67% | Details | |
| 1/13/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
28.38 (17.02) |
-40.03% | Details | |
| 1/13/2026 | Biomea Fusion Inc. | BMEA | New Coverage | Buy (N/A) |
1.46 (1.23) |
-15.75% | Details | |
| 1/13/2026 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
0.31 (3.62) |
1067.74% | Details | |
| 1/13/2026 | Jasper Therapeutics | JSPR | New Coverage | Buy (N/A) |
1.48 (0.46) |
-68.92% | Details |
